drug
belumosudil mesylate
Marketedupdated 6mo agoby Kadmon Pharmaceuticals LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(5)
approval · 5
Jul 16, 2021
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Nov 9, 2023
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Apr 10, 2024
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Dec 30, 2024
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Jan 15, 2026
approval
REZUROCK (BELUMOSUDIL MESYLATE) — FDA approval
belumosudil mesylate
→
Trials studying belumosudil mesylate
- phase1A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects
- phase1A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects
- phase1A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 16, 2028
~1.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Jul 14, 2042method-of-use (U-4014)US 12097202
- Apr 9, 2035method-of-use (U-3369)US 11311541
- Jun 20, 2034compositionUS 8357693
- Oct 7, 2033method-of-use (U-3246)US 10183931
- Oct 7, 2033method-of-use (U-3246)US 10696660
FDA exclusivities (2)
- Jul 16, 2028ODE-362Orphan Drug (7y)1.7y
- Jul 16, 2026NCENew Chemical Entity (5y)
News(1)
- CinRx teams with Sam Waksal's Graviton on ROCK2 for PAH, other cardio conditionsSam Waksal is doubling down on ROCK2 after his first work on the target led to the chronic graft-versus-host disease medicine Rezurock. Now, the Graviton Bioscience CEO is teaming up with a cardio…endpoints · 17d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that